



ASX Announcement

07 March 2025

Cambium Bio Strengthens Board with Appointment of Li-Chien Chiu

Sydney, Australia; 07 March 2025: Cambium Bio Limited (ASX:CMB) (**Cambium Bio, Cambium** or **Company**), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to announce the appointment of Mr. Li-Chien Chiu to its Board of Directors, effective immediately.

Mr. Chiu is the Chairman of Hocheng Corporation (TWO:1810), a publicly-listed industrial company on the Taipei Stock Exchange with a market capitalization of approximately 5.2 billion TWD. He brings extensive corporate leadership experience to Cambium Bio, having led Hocheng Corporation since 2003. Following Cambium Bio's recent capital raising, Mr. Chiu holds 800,357 shares, representing a 4.38% stake in the Company.

Cambium Bio CEO, **Karolis Rosickas**, commented: "We are delighted to welcome Li-Chien Chiu to our Board of Directors. His extensive corporate experience and significant strategic investment in Cambium Bio demonstrates strong confidence in our vision and clinical programs. Mr. Chiu's leadership expertise and international business acumen will be invaluable as we advance our lead candidate, Elate Ocular®, through Phase 3 clinical trials and pursue our out-licensing strategy."

Li-Chien Chiu stated: "I am honoured to join the Board of Cambium Bio at this pivotal time in the Company's development. The innovative regenerative medicine platform being developed has tremendous potential to address significant unmet medical needs, particularly in dry eye disease. I look forward to contributing to Cambium Bio's growth strategy and helping to guide the Company toward clinical and commercial success."

Mr. Chiu brings over 35 years of corporate leadership experience across multiple industries. His career includes senior roles at Hostan Corporation (Vice President, 1998-2003), Hocheng Corporation (Marketing Department Manager, 1996-1998), Sanquan Construction (Executive Director, 1993-1996), Hocheng Corporation North America Branch (Vice President, 1990-1993), and Hanyang Construction (Construction Site Director, 1988-1990). He holds a degree from the University of San Francisco, which he obtained in 1987.

The appointment of Mr. Chiu further strengthens Cambium Bio's Board, which has recently been enhanced with the additions of Dr. ChiTai Chang in October 2024 and Clinical A/Prof Chandra Bala in November 2024. Together with existing Board members, this expanded leadership team possesses the diverse expertise necessary to guide Cambium Bio through its next phase of growth and clinical development.

- ENDS -

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:

Helen Leung
Corporate Secretary
info@cambium.bio
1 300 995 098

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	CAMBIUM BIO LIMITED
ABN	13 127 035 358

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Li-Chien Chiu
Date of appointment	7 March 2025

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
800,357 fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Number & class of Securities
N/A	

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.